Aravive Inc. receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency |
|---|
Investing.com - Aravive (NASDAQ:ARAV) reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. Aravive announced earnings...
Aravive, Inc. (ARAV) reported Q3 EPS of ($0.51), $0.11 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.96 million versus the consensus estimate...
Investors in Aravive, Inc. (NASDAQ:ARAV) need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 20, 2019 $10.00 Call had...
Investors in Versartis, Inc. (NASDAQ:VSAR) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 16, 2018 $5.00 Call had...
Shares of Versartis Inc. (NASDAQ:VSAR) tanked 86% after the company reported failure of its somavaratan drug in Phase 3 VELOCITY trialConagra Brand’s (NYSE:CAG) shares...
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The Company is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 154.65 | 155.23 | 150.64 | +2.92 | +1.92% | 82.97M | NASDAQ | |||
| 107.64 | 108.18 | 103.12 | +4.74 | +4.61% | 48.11M | NASDAQ | |||
| 267.56 | 268.77 | 260.08 | +10.79 | +4.20% | 50.36M | NASDAQ | |||
| 102.00 | 102.41 | 98.08 | -0.18 | -0.18% | 115.86M | NASDAQ | |||
| 221.73 | 222.59 | 211.50 | +10.84 | +5.14% | 66.07M | NASDAQ | |||
| 362.95 | 364.18 | 354.18 | +1.47 | +0.41% | 6.25M | NASDAQ | |||
| 43.59 | 43.90 | 43.25 | -0.17 | -0.39% | 22.95M | NYSE | |||
| 159.70 | 160.21 | 154.11 | +3.47 | +2.22% | 3.45M | NASDAQ | |||
| 191.62 | 193.78 | 184.40 | +5.56 | +2.99% | 45.68M | NASDAQ | |||
| 463.26 | 466.24 | 450.51 | +8.04 | +1.77% | 1.34M | NYSE | |||
| 105.50 | 107.35 | 103.72 | +0.05 | +0.05% | 16.80M | NYSE | |||
| 21.61 | 22.38 | 21.08 | -0.64 | -2.88% | 4.41M | NYSE | |||
| 17.17 | 17.26 | 16.18 | +0.39 | +2.32% | 2.31M | NASDAQ | |||
| 22.57 | 23.02 | 22.24 | -0.48 | -2.08% | 131.92K | NYSE | |||
| 116.90 | 117.21 | 114.77 | +0.40 | +0.34% | 2.17M | NYSE |